verazo
libbs farmacÊutica ltda - bortezomibe - antineoplasicos citotoxicos
melleril
bl indÚstria otica ltda - cloridrato de tioridazina - neurolepticos
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - agentes antineoplásicos - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - agentes antineoplásicos - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
verzenios
eli lilly nederland b.v. - abemaciclib - neoplasias do peito - agentes antineoplásicos - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
tykerb
novartis biociencias s.a - ditosilato de lapatinibe - antineoplasico
zaltrap
sanofi-aventis farmacÊutica ltda - aflibercepte - outros antineoplasicos
zaltrap
sanofi medley farmacÊutica ltda. - aflibercepte - outros antineoplasicos
gutal 1000 mg/g pré-mistura medicamentosa para alimento medicamentoso para leitões
huvepharma sa - Óxido de zinco 1000.0 mg - pré-mistura medicamentosa para alimento medicamentoso - Óxido de zinco - suínos (leitões desmamados)
yargesa
piramal critical care b.v. - miglustat - doença de gaucher - outro aparelho digestivo e metabolismo produtos, - yargesa é indicado para o tratamento oral de pacientes adultos com leve a moderada de gaucher do tipo 1 da doença. yargesa só pode ser utilizado no tratamento de doentes para os quais a terapia de reposição enzimática é inadequados. yargesa é indicado para o tratamento de progressiva manifestações neurológicas em pacientes adultos e pediátricos com niemann-pick tipo c da doença.